Hersh C - Search Results

1

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.

Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, Hersh C, Craner M, Bale C, Chaudhry B, Gunzler DD, Love TE, Gerry S, Coles A, Cohen JA, Evangelou N. Ontaneda D, et al. Among authors: hersh c. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. Epub 2020 Apr 19. Contemp Clin Trials. 2020. PMID: 32320842

2

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Hersh CM, Cohen JA. Hersh CM, et al. Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Immunotherapy. 2014. PMID: 24762071 Review.

3

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D. Hersh CM, et al. Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29. Int J Neurosci. 2015. PMID: 25271798 Free PMC article.

4

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D. Hersh CM, et al. Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8. Mult Scler Relat Disord. 2016. PMID: 27919497

5

Wellness and the Role of Comorbidities in Multiple Sclerosis.

Moss BP, Rensel MR, Hersh CM. Moss BP, et al. Neurotherapeutics. 2017 Oct;14(4):999-1017. doi: 10.1007/s13311-017-0563-6. Neurotherapeutics. 2017. PMID: 28785958 Free PMC article. Review.

6

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D. Hersh CM, et al. Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep. Mult Scler J Exp Transl Clin. 2017. PMID: 28890796 Free PMC article.

7

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Vollmer B, et al. Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487. Neurol Clin Pract. 2018. PMID: 30140580 Free PMC article.

8

The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, Varga S, Herrera V, Ko JJ. Hua LH, et al. J Manag Care Spec Pharm. 2019 Apr;25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. J Manag Care Spec Pharm. 2019. PMID: 30917079 Free PMC article.

9

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.

Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Vollmer B, et al. J Neurol Sci. 2019 Dec 15;407:116498. doi: 10.1016/j.jns.2019.116498. Epub 2019 Oct 15. J Neurol Sci. 2019. PMID: 31644992 Free article.

10

Comparative effectiveness studies in multiple sclerosis.

Hersh CM, Hua LH. Hersh CM, et al. Neurodegener Dis Manag. 2020 Jun;10(3):113-118. doi: 10.2217/nmt-2020-0015. Epub 2020 Jun 5. Neurodegener Dis Manag. 2020. PMID: 32501735 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

374 results

Search Page